Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
specificStage III includes: IIIA: (T1, N2, M0, Any G); (T2, N1, M0, Any G); IIIB: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in t
5
Centers
5
Active Trials
—
Cancer Funding
Top Centers for Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8(5)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 60.0 |
| 2 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive Active Research Program | 60.0 |
| 3 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 60.0 |
| 4 | Moffitt Cancer CenterTampa, FL NCI Comprehensive Active Research Program | 60.0 |
| 5 | Boston University Cancer CenterBoston, MA Active Research Program | 60.0 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →